Influenza activity remains elevated in most of the country, according to the latest FluView report from the CDC for the week of January 13-19.
Influenza activity remains elevated in most of the country, according to the latest FluView report from the CDC for the week of January 13-19.
Some national indicators are declining while others are increasing. In general, influenza-like-illness activity levels are declining in the South, Southeast, New England, and the Midwest, but increasing in the Mid-Atlantic, Southwest, and the Northwest.
Key indicators reflecting severity, such as hospitalizations and deaths, increased significantly again this week, with the greatest impact among people aged 65 and older. Of the 6,191 influenza-associated hospitalizations that have been reported this season, 50.1% have been among people aged 65 and older.
“While some part of the United States continue to experience declines in influenza activity, there are others that are still experiencing increases in the virus resulting in hospitalizations and death,” said Formulary Advisor Abimbola Farinde, PharmD, MS, clinical staff pharmacist at Clear Lake Regional Medical Center, in Webster, Texas.
“It is important for healthcare providers to reiterate to the public the importance of vaccination as a preventive measure, and the use of antiviral treatments as a means of curtailing the rising incidences and at times possible fatality that can result from untreated flu-related complications,” Dr Farinde said.
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More